Pliant Therapeutics, Inc.
PLRX
$1.38
-$0.09-6.12%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 6.69% | 1.87% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 10.53% | -14.02% | |||
| Operating Income | -10.53% | 14.02% | |||
| Income Before Tax | -12.94% | 13.90% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -12.94% | 13.90% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -12.94% | 13.90% | |||
| EBIT | -10.53% | 14.02% | |||
| EBITDA | -10.64% | 14.02% | |||
| EPS Basic | -12.26% | 14.08% | |||
| Normalized Basic EPS | -12.26% | 14.08% | |||
| EPS Diluted | -12.26% | 14.08% | |||
| Normalized Diluted EPS | -12.26% | 14.08% | |||
| Average Basic Shares Outstanding | 0.61% | 0.20% | |||
| Average Diluted Shares Outstanding | 0.61% | 0.20% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||